Diabetic Macular Oedema (DMO) Classification
Classification of diabetic macular oedema combining historical ETDRS clinically significant macular oedema (CSME) criteria with modern OCT-based centre-involving (CI-DMO) versus non-centre-involving (NCI-DMO) terminology. Drives anti-VEGF / laser decisions.
Score interpretation
→ Routine screening interval per DR grade. Optimise HbA1c, BP, lipids.
→ Hospital eye service referral within 13 weeks. Observation with OCT every 4–6 months. Focal/grid laser if exudate threatens fovea.
→ Per DRCR.net Protocol V — observation with monthly visits is acceptable if VA ≥6/7.5. Initiate anti-VEGF if VA drops or central thickness increases.
→ Intravitreal anti-VEGF (ranibizumab, aflibercept, faricimab, brolucizumab) per NICE TA346/824/989. Loading 4–6 monthly injections then PRN/T&E. Sustained-release dexamethasone implant (Ozurdex) if pseudophakic / poor anti-VEGF response. Consider focal laser for refractory non-centre fluid.
Interpretation bands for the DMO. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Ranibizumab · Anti-VEGF (intravitreal injection)
- Bevacizumab (Intravitreal) · Anti-VEGF (Vascular Endothelial Growth Factor Inhibitor)
- Aflibercept 2mg/0.05mL Intravitreal Injection (Eylea) · Anti-VEGF agent (intravitreal)
- Faricimab (Intravitreal) · Anti-VEGF and Anti-Ang-2 — Bispecific Monoclonal Antibody
- Brolucizumab (Intravitreal) · Anti-VEGF — Single-chain Antibody Fragment (scFv)
- Pegaptanib Sodium · Anti-VEGF (RNA Aptamer) — Neovascular AMD
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.